Frankfurt, September 5, 2007 – Nanostart AG has increased its equity investment in BioMicro Systems Inc., a leading provider of nanotechnology-based analysis tools based in Salt Lake City, Utah, raising its shareholding to approximately nine percent. In addition to Nanostart AG, two U.S. venture capital investors also participated in this additional round of financing. Nanostart has been invested in BioMicro Systems since 2004.

BioMicro is one of the leading providers in the lucrative market for nanotech-based analysis tools and develops, produces and distributes these for applications in pharmaceuticals and research. The company expects to reach breakeven already in the current year. BioMicro would particularly like to use the resources from the latest round of financing to expand production and to exploit new opportunities for growth.

BioMicro already signed an OEM agreement with NimbleGen Systems, Inc. in the spring of this year. NimbleGen, with headquarters in Madison, Wisconsin, is one of the leading suppliers within the market for microarray products and services. NimbleGen, which produced sales of approx. USD 14 million in 2006, was acquired by Roche Diagnostics in a trade sale in the summer of 2007 for USD 272 million.

"The acquisition of NimbleGen by Roche Diagnostics clearly demonstrates the kind of premiums that are being paid on the U.S. market for life science companies," said Andreas Kröll, senior portfolio manager at Nanostart AG, adding, "We are thus particularly pleased that the increase of our shareholding in BioMicro gives us the opportunity to further expand our strategic position in the U.S. venture capital market."


About Nanostart:
Nanostart AG is Europe’s leading nanotechnology investment company, with headquarters in Frankfurt, Germany. The company is organized into two divisions: the Portfolio Division, which manages its own investment holdings; and the Financial Services Division, which advises financial service providers on investing in the nanotechnology sector.


About BioMicro Systems:
BioMicro Systems, Inc. is a private company that serves the life sciences community by developing and marketing biological research products based on its proprietary microfluidic and microarray technologies.


DISCLAIMER:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax:     +49 (0)69-21 93 96 122
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it